Homocysteine induced cerebrovascular dysfunction: A link to alzheimer’s disease etiology

Open Neurology Journal

Volumn 9, Issue , 2015, Pages 9-14

  Kamat, P K ^a   Vacek, J C ^a   Kalani, A ^a   Tyagi, N ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

Alzheimer s disease; Blood brain barrier; Cerebrovascular pathology; Homocysteine; Vascular dementia

Indexed keywords

AMYLOID BETA PROTEIN; HOMOCYSTEINE; TAU PROTEIN;

ALZHEIMER DISEASE; ANGIOGENESIS; APOPTOSIS; ARTICLE; BLOOD BRAIN BARRIER; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; COGNITION; DIET SUPPLEMENTATION; DISEASE ASSOCIATION; ENDOTHELIAL DYSFUNCTION; HUMAN; HYPERHOMOCYSTEINEMIA; MEMBRANE PERMEABILITY; MICROANGIOPATHY; MULTIINFARCT DEMENTIA; NERVE DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NEUROFIBRILLARY TANGLE; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN METABOLISM; PROTEIN PHOSPHORYLATION; QUALITY OF LIFE;

EID: 84937779820     PISSN: None     EISSN: 1874205X     Source Type: Journal    
DOI: 10.2174/1874205X01509010009     Document Type: Article

References (62)

1. [1] Prudova A, Bauman Z, Braun A, Vitvitsky V, Lu SC, Banerjee R. S-adenosylmethionine stabilizes cystathionine beta-synthase and modulates redox capacity. Proc Natl Acad Sci USA 2006; 103: 6489-94.
2. [2] Garcia A, Zanibbi K. Homocysteine and cognitive function in elderly people. Cmaj 2004; 171: 897-904.
3. [3] Kamat PK, Kalani A, Givvimani S, Sathnur PB, Tyagi SC, Tyagi N. Hydrogen sulfide attenuates neurodegeneration and neurovascular dysfunction induced by intracerebral-administered homocysteine in mice. Neuroscience 2013; 252: 302-19.
4. [4] Zhuo JM, Wang H, Pratico D. Is hyperhomocysteinemia an Alzheimer's disease (AD) risk factor, an AD marker, or neither? Trends Pharmacol Sci 2011; 32: 562-71.
5. [5] Brustolin S, Giugliani R, Felix TM. Genetics of homocysteine metabolism and associated disorders. Braz J Med Biol Res 2010; 43:1-7.
6. [6] Nilsson K, Gustafson L, Hultberg B. Plasma homocysteine and cognition in elderly patients with dementia or other psychogeriatric diseases. Dement Geriatr Cogn Disord 2010; 30: 198-204.
7. [7] Ho V, Massey TE, King WD. Influence of thymidylate synthase gene polymorphisms on total plasma homocysteine concentrations. Mol Genet Metab 2010; 101: 18-24.
8. [8] Kuszczyk M, Gordon-Krajcer W, Lazarewicz JW. Homocysteineinduced acute excitotoxicity in cerebellar granule cells in vitro is accompanied by PP2A-mediated dephosphorylation of tau. Neurochem Int 2009; 55: 174-80.
9. [9] Park YJ, Jang Y, Kwon YH. Protective effect of isoflavones against homocysteine-mediated neuronal degeneration in SHSY5Y cells. Amino Acids 2010; 39: 785-94.
10. [10] Ataie A, Sabetkasaei M, Haghparast A, Moghaddam AH, Kazeminejad B Neuroprotective effects of the polyphenolic antioxidant agent, Curcumin, against homocysteine-induced cognitive impairment and oxidative stress in the rat. Pharmacol Biochem Behav 2010; 96: 378-85.
11. [11] Yan SK, Chang T, Wang H, Wu L, Wang R, Meng QH. Effects of hydrogen sulfide on homocysteine-induced oxidative stress in vascular smooth muscle cells. Biochem Biophys Res Commun 2006; 351: 485-91.
12. [12] Chiang PK, Gordon RK, Tal J, Zeng GC, Doctor BP, Pardhasaradhi K, McCann PP. S-Adenosylmethionine and methylation. Faseb J 1996; 10: 471-80.
13. [13] Caudill MA, Dellschaft N, Solis C, et al. Choline intake, plasma riboflavin, and the phosphatidyletha-nolamine N-methyltransferase G5465A genotype predict plasma homocysteine in folate-deplete Mexican-American men with the methylenetetrahydrofolate reductase 677TT genotype. J Nutr 2009; 139: 727-33.
14. [14] Aisen PS, Schneider LS, Sano M, et al. High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial. JAMA 2008; 300: 1774-83.
15. [15] Chen J, Zhang I, Cheng L, Li Y. The effect of polymorphisms of MTHER gene and vitamin B on hyperhomocysteinemia. J Tongji Med Univ 2001; 21: 17-20.
16. [16] Folstein M, Liu T, Peter I, et al. The homocysteine hypothesis of depression. Am J Psychiatry 2007; 164: 861-67.
17. [17] Moore E, Mander A, Ames D, Carne R, Sanders K, Watters D Cognitive impairment and vitamin B12: a review. Int Psychogeriatr 2012; 24: 541-56.
18. [18] Sponne IE, Gaire D, Stabler SP, et al. Inhibition of vitamin B12 metabolism by OH-cobalamin c-lactam in rat oligodendrocytes in culture: a model for studying neuropathy due to vitamin B12 deficiency. Neurosci Lett 2000; 3: 191-4.
19. [19] Kruman, II, Mouton PR, Emokpae R, Jr., Cutler RG, Mattson MP. Folate deficiency inhibits proliferation of adult hippocampal progenitors. Neuroreport 2000; 16: 1055-59.
20. [20] Kronenberg G, Colla M, Endres M. Folic acid, neurodegenerative and neuropsychiatric disease. Curr Mol Med 2009; 9: 315-23.
21. [21] Zhang CE, Tian Q, Wei W, et al. Homocysteine induces tau phosphorylation by inactivating protein phosphatase 2A in rat hippocampus. Neurobiol Aging 2008; 29: 1654-65.
22. [22] Vezzani A. Inflammation and epilepsy. Epilepsy Curr 2005; 5:1-6.
23. [23] Kalani A, Kamat PK, Givvimani S, et al. Nutri-epigenetics ameliorates blood-brain barrier damage and neurodegeneration in hyperhomocysteinemia: role of folic acid. J Mol Neurosci 2014; 2: 202-15.
24. [24] Rivera J, Sobey CG, Walduck AK, Drummond GR. Nox isoforms in vascular pathophysiology: insights from transgenic and knockout mouse models. Redox Rep 2010; 15: 50-63.
25. [25] Troen AM. The central nervous system in animal models of hyperhomocysteinemia. Prog Neuropsychopharmacol Biol Psychiatry 2005; 29: 1140-51.
26. [26] Kalani A, Kamat PK, Familtseva A, et al. Role of microRNA29b in blood-brain barrier dysfunction during hyperhomocysteinemia: an epigenetic mechanism. J Cereb Blood Flow Metab. 2014; 7: 1212-22.
27. [27] Tyagi N, Qipshidze N, Munjal C, et al. Tetrahydrocurcumin ameliorates homocysteinylated cytochrome-c mediated autophagy in hyperhomocysteinemia mice after cerebral ischemia. J Mol Neurosci 2012; 47: 128-38.
28. [28] Rhodehouse BC, Mayo JN, Beard RS Jr, Chen CH, Bearden SE. Opening of the blood-brain barrier before cerebral pathology in mild hyperhomocysteinemia. PLoS One 2013; 5: e63951.
29. [29] Peng H, Cheng H, Xing HY, Li G, Yu FQ. Effect mechanism of Hcy on damage of BBB and the intervention of the compounded vitamin in rat. Zhonghua Yi Xue Za Zhi 2010; 90: 1642-44.
30. [30] Yong VW, Power C, Forsyth P, Edwards DR. Metalloproteinases in biology and pathology of the nervous system. Nat Rev Neurosci 2001; 2: 502-11.
31. [31] Lee WJ, Shin CY, Yoo BK, et al. Induction of matrix metalloproteinase-9 (MMP-9) in lipopolysaccharide-stimulated primary astrocytes is mediated by extracellular signal-regulated protein kinase 1/2 (Erk1/2). Glia 2003; 41: 15-24.
32. [32] Klein T, Bischoff R. Physiology and pathophysiology of matrix metalloproteases. Amino Acids 2011; 41: 271-90.
33. [33] Dal-Pizzol F, Rojas HA, dos Santos EM, et al. Matrix metalloproteinase-2 and metalloproteinase-9 activities are associated with blood-brain barrier dysfunction in an animal model of severe sepsis. Mol Neurobiol 2013; 48: 62-70.
34. [34] De Caterina R, Massaro M, Scoditti E, Annunziata Carluccio M Pharmacological modulation of vascular inflammation in atherothrombosis. Ann N Y Acad Sci 2010; 1207: 23-31.
35. [35] Abdulle AM, Pathan JY, Moussa N, Gariballa S. Association between homocysteine and endothelial dysfunction markers in stroke disease. Nutr Neurosci 2010; 13: 2-6.
36. [36] Salmina AB, Inzhutova AI, Malinovskaya NA, Petrova MM. Endothelial dysfunction and repair in Alzheimer-type neurodegeneration: neuronal and glial control. J Alzheimers Dis 2010; 22: 17-36.
37. [37] Cook-Mills JM. VCAM-1 signals during lymphocyte migration: role of reactive oxygen species. Mol Immunol 2002; 39: 499-08.
38. [38] Kalaria RN. Vascular basis for brain degeneration: faltering controls and risk factors for dementia. Nutr Rev 2010; 68 Suppl 2: S74-87.
39. [39] Zlokovic BV. Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders. Nat Rev Neurosci 2011; 12: 723-38.
40. [40] Bell RD. The imbalance of vascular molecules in Alzheimer's disease. J Alzheimers Dis 2012; 32: 699-09.
41. [41] Quadri P, Fragiacomo C, Pezzati R, et al. Homocysteine, folate, and vitamin B-12 in mild cognitive impairment, Alzheimer disease, and vascular dementia. Am J Clin Nutr 2004; 80: 114-22.
42. [42] Dubois MF, Hebert R. The incidence of vascular dementia in Canada: a comparison with Europe and East Asia. Neuroepidemiology 2001; 20: 179-187.
43. [43] Desai BS, Schneider JA, Li JL, Carvey PM, Hendey B. Evidence of angiogenic vessels in Alzheimer's disease. J Neural Transm 2009; 116: 587-97.
44. [44] Pirchl M, Ullrich C, Humpel C. Differential effects of short-and long-term hyperhomocysteinaemia on cholinergic neurons, spatial memory and microbleedings in vivo in rats. Eur J Neurosci 2010; 32: 1516-27.
45. [45] Herrmann W, Obeid R. Homocysteine: a biomarker in neurodegenerative diseases. Clin Chem Lab Med 2011; 49: 435-41.
46. [46] Humpel C. Chronic mild cerebrovascular dysfunction as a cause for Alzheimer's disease? Exp Gerontol 2011; 46: 225-32.
47. [47] Wehling M, Groth H. Challenges of longevity in developed countries: vascular prevention of dementia as an immediate clue to tackle an upcoming medical, social and economic stretch. Neurodegener Dis 2011; 8: 275-82.
48. [48] Agnati LF, Genedani S, Rasio G, et al. Studies on homocysteine plasma levels in Alzheimer's patients. Relevance for neurodegeneration. J Neural Transm 2005; 112: 163-69.
49. [49] Streck EL, Bavaresco CS, Netto CA, Wyse AT. Chronic hyperhomocysteinemia provokes a memory deficit in rats in the Morris water maze task. Behav Brain Res 2004; 153: 377-81.
50. [50] Hachinski V. Commentary on "Vascular cognitive impairment: today and tomorrow." Vascular cognitive impairment: yesterday, today, and tomorrow. Alzheimers Dement 2006; 2: 198-99.
51. [51] Breteler MM. Vascular risk factors for Alzheimer's disease: an epidemiologic perspective. Neurobiol Aging 2000; 21: 153-60.
52. [52] Troen A, Rosenberg. Homocysteine and cognitive function. Semin Vasc Med 2005; 2: 209-14.
53. [53] Kamat PK, Rai S, Swarnkar S, et al. Okadaic acid-induced Tau phosphorylation in rat brain: role of NMDA receptor. Neuroscience. 2013; 238: 97-13
54. [54] Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002; 297: 353-56.
55. [55] Isobe C, Abe T, Terayama Y. Homocysteine may contribute to pathogenesis of RNA damage in brains with Alzheimer's disease. Neurodegener Dis 2009; 6: 252-57.
56. [56] Tiraboschi P, Sabbagh MN, Hansen LA, et al. Alzheimer disease without neocortical neurofibrillary tangles: "a second look". Neurology 2004; 62: 1141-47.
57. [57] Rhodehouse BC, Erickson MA, Banks WA, Bearden SE. Hyperhomocysteinemic mice show cognitive impairment without features of Alzheimer's disease phenotype. J Alzheimers Dis 2013; 35: 59-66.
58. [58] Chai GS, Jiang X, Ni ZF, et al. Betaine attenuates Alzheimer-like pathological changes and memory deficits induced by homocysteine. J Neurochem 2013; 124: 388-96.
59. [59] Zhang CE, Wei W, Liu YH, et al. Hyperhomocysteinemia increases beta-amyloid by enhancing expression of gammasecretase and phosphorylation of amyloid precursor protein in rat brain. Am J Pathol 2009; 174: 1481-91.
60. [60] Kruman II, Kumaravel TS, Lohani A, et al. Folic acid deficiency and homocysteine impair DNA repair in hippocampal neurons and sensitize them to amyloid toxicity in experimental models of Alzheimer's disease. J Neurosci. 2002; 5: 1752-62.
61. [61] Koladiya RU, Jaggi AS, Singh N, Sharma BK. Ameliorative role of Atorvastatin and Pitavastatin in L-Methionine induced vascular dementia in rats. BMC Pharmacol 2008; 8: 14.
62. [62] Pacheco-Quinto J, Rodriguez de Turco EB, DeRosa S, et al. Hyperhomocysteinemic Alzheimer's mouse model of amyloidosis shows increased brain amyloid beta peptide levels. Neurobiol Dis 2006; 22: 651-56.